Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder / Joachim F. Wernicke en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 30-35 Título : Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder : A prospective, placebo-controlled assessment Tipo de documento: texto impreso Autores: Joachim F. Wernicke, Autor ; Lenard Adler, Autor ; Thomas J. Spencer, Autor Fecha de publicación: 2023 Artículo en la página: pp. 30-35 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno por Déficit de Atención con Hiperactividad, Propilaminas, Índice de gravedad de la enfermedad Resumen: Drugs that affect neurotransmitter release can induce changes in neuroregulation during chronic administration. Thus, in addition to recurrence of symptoms of the illness, discontinuation of treatment can be associated with clinical signs and symptoms related to these changes. Atomoxetine, a new drug approved in the United States for treatment of attention deficit/hyperactivity disorder (ADHD), is associated with blockade of the presynaptic norepinephrine transporter. Link: ./index.php?lvl=notice_display&id=30975 [artículo] Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder : A prospective, placebo-controlled assessment [texto impreso] / Joachim F. Wernicke, Autor ; Lenard Adler, Autor ; Thomas J. Spencer, Autor . - 2023 . - pp. 30-35. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 30-35 Palabras clave: Trastorno por Déficit de Atención con Hiperactividad, Propilaminas, Índice de gravedad de la enfermedad Resumen: Drugs that affect neurotransmitter release can induce changes in neuroregulation during chronic administration. Thus, in addition to recurrence of symptoms of the illness, discontinuation of treatment can be associated with clinical signs and symptoms related to these changes. Atomoxetine, a new drug approved in the United States for treatment of attention deficit/hyperactivity disorder (ADHD), is associated with blockade of the presynaptic norepinephrine transporter. Link: ./index.php?lvl=notice_display&id=30975

---

1 (1 - 1 / 1)